journal article·2024-09Open access

Development of a Mouse Cardiac Sarcoidosis Model Using Carbon Nanotubes

Sophie Van Remortel, Yousef Risha, Sandrine Parent, Vidhya Nair, David H. Birnie, Darryl R. Davis

Advanced Biology· Volume 8· Issue 9

Abstract

Abstract Sarcoidosis, a granulomatous disorder of unknown etiology affecting multiple organs. It is often a benign disease but can have significant morbidity and mortality when the heart is involved (often presenting with clinical manifestations such as conduction irregularities and heart failure). This study addresses a critical gap in cardiac sarcoidosis (CS) research by developing a robust animal model. The absence of a reliable animal model for cardiac sarcoidosis is a significant obstacle in advancing understanding and treatment of this condition. The proposed model utilizes carbon nanotube injection and transverse aortic constriction as stressors. Intramyocardial injection of carbon nanotubes induces histiocytes typical of sarcoid granulomas in the heart but shows limited effects on fibrosis or cardiac function. Priming the immune system with transverse aortic constriction prior to intramyocardial injection of carbon nanotubes enhances cardiac fibrosis, diminishes cardiac function, and impairs cardiac conduction. This novel, easily executable model may serve as a valuable tool for disease profiling, biomarker identification, and therapeutic exploration.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Sarcoidosis and Beryllium Toxicity Research · Occupational exposure and asthma · S100 Proteins and Annexins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

University of Ottawa Heart Institute Division of Cardiology Department of Medicine University of Ottawa Ottawa K1Y4W7 Canada

Department of Pathology and Laboratory Medicine Ottawa Hospital and Faculty of Medicine University of Ottawa Ottawa K1H8M5 Canada

Department of Cellular and Molecular Medicine University of Ottawa Ottawa K1H8M5 Canada

Funding

Canadian Institutes of Health Research · Natural Sciences and Engineering Research Council of Canada

References (25)

Show source-provided references
1. 10.1016/j.jacc.2016.03.60510.1016/j.jacc.2016.03.605 ↗
2. 10.1161/CIRCULATIONAHA.114.01152210.1161/CIRCULATIONAHA.114.011522 ↗
3. 10.1016/j.cjca.2013.02.00410.1016/j.cjca.2013.02.004 ↗
4. 10.1016/j.hrthm.2014.03.04310.1016/j.hrthm.2014.03.043 ↗
5. 10.1080/1040844060057023310.1080/10408440600570233 ↗
6. 10.1007/s12199-008-0064-710.1007/s12199-008-0064-7 ↗
7. 10.1016/j.pharmthera.2008.10.00910.1016/j.pharmthera.2008.10.009 ↗
8. 10.1378/chest.06-211410.1378/chest.06-2114 ↗
9. 10.1164/ajrccm/148.4_Pt_1.97410.1164/ajrccm/148.4_Pt_1.974 ↗
10. 10.1165/rcmb.2010-0401OC10.1165/rcmb.2010-0401OC ↗
11. 10.3390/ijms14122385810.3390/ijms141223858 ↗
12. 10.4172/2157-7439.100034010.4172/2157-7439.1000340 ↗
13. 10.1165/rcmb.2015-0332OC10.1165/rcmb.2015-0332OC ↗
14. 10.7150/thno.1813310.7150/thno.18133 ↗
15. 10.1152/ajplung.00289.201710.1152/ajplung.00289.2017 ↗
16. 10.1016/j.bbrc.2018.06.06110.1016/j.bbrc.2018.06.061 ↗
17. 10.1165/rcmb.2018-0346OC10.1165/rcmb.2018-0346OC ↗
18. 10.1165/rcmb.2018-0365OC10.1165/rcmb.2018-0365OC ↗
19. 10.1007/s00441-016-2526-310.1007/s00441-016-2526-3 ↗
20. 10.1161/JAHA.123.03047810.1161/JAHA.123.030478 ↗
21. 10.3389/fimmu.2020.0144310.3389/fimmu.2020.01443 ↗
22. 10.1172/jci.insight.16329710.1172/jci.insight.163297 ↗
23. 10.1038/s41467-021-25180-810.1038/s41467-021-25180-8 ↗
24. 10.1016/j.biomaterials.2020.12001010.1016/j.biomaterials.2020.120010 ↗
25. 10.1111/acel.1317410.1111/acel.13174 ↗